newsfilter

Outlook of Nov 11, 2026. Latest Diagnostics & Research outlook →

Diagnostics & Research — industry outlook

  • Period: 2026-10-21 to 2026-11-11
  • Events: 19
  • Generated: 2026-11-11T07:30:00.005Z

Aggressive Financial Guidance & Acceleration

MEDP raised 2026 full-year revenue guidance to $2.835 billion to $2.855 billion and EBITDA to $638 million to $652 million, reflecting 12% to 12.8% revenue growth and 14.4% to 16.9% EBITDA growth. IQV increased 2026 full-year revenue guidance to $17.35 billion to $17.50 billion and EBITDA to $4.025 billion to $4.055 billion, targeting $12.90 to $13.00 in diluted EPS. GH raised 2026 revenue guidance to $1.36 billion to $1.37 billion, driven by ~38% to 40% YoY growth, and increased screening volume guidance to 285,000 to 290,000 tests. NTRA raised 2026 revenue guidance to $3.005 billion to $3.035 billion and set a long-term target to double revenue to $6 billion by 2029. LH increased 2026 enterprise revenue growth to 5.9% to 6.7% and adjusted EPS guidance to $18.30 to $18.70. RVTY raised 2026 pro forma revenue to approximately $2.86 billion and EBITDA margin to 28.8%. CSTL increased 2026 revenue guidance to $385 million to $395 million and reiterated 50% to 52% growth for TissueCipher volume. RDNT raised 2026 imaging center revenue to $2.385 billion to $2.435 billion and adjusted EBITDA to $350 million to $363 million. NEO raised 2026 revenue to $807 million to $809 million and adjusted EBITDA to $60 million. CRL raised 2026 non-GAAP EPS to $11.35 to $12.55. MYGN raised 2026 revenue midpoint to $785 million.

Pricing, Reimbursement & Regulatory Headwinds

LH anticipates PAMA implementation in 2027 with a preliminary impact of $125 million, though management views this as the "toughest year" with impacts expected to be lower in 2028-2029. NTRA projects 2027 Signatera ASP of $1,450, targeting $2,000+ long-term as Medicare coverage expands to additional tumor types. GH faces CMS claims processing delays for the new Garden 360 Liquid CDX code, causing a $10 million to $15 million revenue shift from H2 2026 to H1 2027, with reimbursement expected H1 2027. CRL expects pricing power to cover inflation to materialize in the second half of 2027 due to lag times in backlog execution. GH targets a $200 shield cost per test by end of 2028 (currently $330), with an ASP floor of $700. GRAL lowered full-year ASP to approximately $660 per test due to promotional pricing initiated in September 2026 to drive volume, with an expectation to reduce COGS to approximately $230 per test at scale. OCDX faces structural pricing pressures from China's nationwide IVD guidelines, with provincial implementation starting late 2026 and full impact expected in 2027; China revenue is expected to decline from 8% to 4% to 5% of total revenue by 2027. CRL noted that pricing benefits are expected to begin in H2 2027, not immediately in Q4. MYGN expects modest HCT ASP headwinds averaging 1% to 5% annually, skewing 3% to 4% in recent years. FLGT expects PAMA impact to be minimal due to limited exposure of primary CPT codes. RDNT estimates a $5 million negative revenue impact from the 2027 Medicare conversion factor reduction, contingent on potential Congressional reversal. CSTL expects steady ASPs for 2027 with no growth modeled, pending CMS decisions on Advanced ADTX pricing (gap fill vs. crosswalk) due by early December 2026. NEO anticipates "relatively low" impact from 2027 Medicare rates.

Operational Efficiency, AI & Margin Expansion

IQV expects AI agents to drive approximately 80 basis points of operational margin expansion, offsetting pass-through mix headwinds. LH targets $125 million in full-year savings from the "Launchpad" initiative to offset PAMA impacts. CRL expects $300 million in cumulative cost savings from the "Create the Future" program over the next four years, driving 2027 margin improvement. RVTY confirmed a sustainable 40%+ incremental adjusted operating margin framework. GH expects $200 shield cost per test by 2028 and is lowering COGS from $410 to $330. RDNT aims to process >75% of studies via clinical AI by Q3 2027 and achieve >50% imaging volume report automation by the same date. FLGT deployed five additional AI applications in Q4 2026, with a transition to a new AI analysis platform to improve scalability. NEO transitioned to the Zyfin RCM platform and Novaseq X sequencers, with efficiency impacts expected in H2 2027. CSTL targets positive adjusted EBITDA for 2026 and 2027. MEDP expects 14.4% to 16.9% EBITDA growth for 2026, though Q4 2027 margins face headwinds from a $20 million cost increase due to a new Cincinnati expansion. LH expects enterprise margin expansion in 2026. RVTY expects Q4 2026 adjusted operating margin slightly above 32%.

M&A, Divestitures & Capital Allocation

LH plans to close BioReference (mid-2027, $250 million revenue impact, $0.15 EPS accretion), Myriad Genetics (early 2027, $160 million revenue, accretive), MLM Medical Labs (closed), and Millennium Health (later in 2026). MYGN signed a definitive agreement to sell its prenatal business to LH for $210 million plus inventory, expecting >100 basis points revenue growth improvement and >500 basis points gross margin improvement post-divestiture. MEDP approved a new $1 billion share repurchase authorization effective October 20, 2026. NTRA announced a leadership transition with Solomon Moscovich replacing Steve Chapman as CEO. RDNT is pending the acquisition of OnRad for $350 million cash plus 5M shares, expected to contribute $190 million to $200 million in revenue and $60 million to $65 million in EBITDA in Year 1. CRL divested its CDMO business, fully integrated in results, and expects to explore M&A in bioanalytical. RVTY expects to divest its China immunodiagnostics business next year. GH is expanding rep productivity and DTC campaigns to drive screening volume. NEO is transitioning leadership with Warren Stone becoming CEO effective January 4, 2027. CSTL remains cash-rich with $278 million in securities. FLGT received a $112.3 million tax refund and maintains $630 million in cash. OCDX is restructuring to deliver over $80 million in annual savings starting in 2027. ACRS secured $50 million in top-up financing, extending cash runway to mid-2029.

Demand Trends, Backlog & Therapeutic Focus

MEDP projects $1.99 billion of its $3.2 billion backlog converting to revenue in 12 months; sees a shift from metabolic demand toward traditional oncology, though RFPs show significant metabolic opportunities. IQV reports EBP funding up >85% YoY to $90 billion, with clinical trial starts up high single digits; expects outsourcing pendulum to swing back to full-service models. NTRA saw Signatera clinical MRD units grow 56% YoY to 316,000 in Q3, with pharma services revenue up ~70% in the first three quarters. GH projects >50% volume growth in oncology, driven by the new GARDEN260-CDX approval for ESR1 monitoring targeting 37,000 patients, and >30% volume growth in Garden 360 Liquid. CRL reports DSA net book-to-bill of 1.09x for four consecutive quarters, with biotech funding robust at approximately $100 billion (trailing 12 months). LH expects BLS backlog conversion of $2.8 billion in the next 12 months from a $8.9 billion backlog, with strong demand in oncology and cardiometabolic sectors. RDNT anticipates advanced imaging (MR, CT, PET-CT) growth outpacing routine imaging due to AI-enabled speed and demographic trends. GRAL expects volume to accelerate post-FDA approval, with Q3 2026 volume growth of 24%. CSTL notes TissueCipher is at ~15% penetration in eligible endoscopy procedures. MEDP notes cancellation drivers have shifted from funding to product failure and prioritization. ACRS pivoted development of ATI-052 to Eosinophilic Esophagitis (EOE) due to capital efficiency, with Phase IIb expected to start early 2027. NEO notes a shift in NGS mix to large panels (50-50 ratio) driving AUP growth. IQV panelists noted a structural shift where emerging biopharma and Chinese companies replace large pharma as primary Phase 1 sponsors, with China's share rising to 43% in 2025.

Strategic Capital Planning & Risk Management

MEDP deferred 2027 guidance until February 2027, citing cancellation volatility as the primary risk. IQV will provide a 2027 framework at an Investor Day on December 1, 2026. LH expects PAMA to be the "toughest year" in 2027 but believes it can be offset by business momentum. CRL expects gradual growth improvement from 2026 levels, targeting 5-7% revenue growth starting 2028. GRAL expects final FDA decision on GALLERY by early Q1 2027, with 2026 cash burn capped at $300 million. GH targets company-wide FCF breakeven by end of 2027 and Screening standalone breakeven by end of 2028. NTRA expects profitability to be achieved "growing into it," with OPEX growing 10% to 12% in 2027. CSTL expects positive EBITDA in 2026 and 2027. RVTY plans to maintain $630 million cash position and targets net debt to EBITDA of 2.0x by year-end. OCDX is restructuring to reduce leverage from 4.5x to below 5.5x through Q2 2028, with $30 million to $35 million in one-time restructuring charges in Q4 2026. FLGT expects to fund therapeutics development with $21 million in 2026 and $13 million in CapEx. ACRS expects to extend cash runway to mid-2029 with the new financing. NEO transitioned RCM systems with temporary impacts normalizing by Q4 2026. RDNT expects $190 million to $200 million revenue from OnRad in Year 1 and $56 million EBITDA target for the 2027 earn-out.